Brief: Regeneron’S Ebola Antibody Recommended By World Health Organization For Investigational Use In Response To Current Bundibugyo Ebolavirus Outbreak
28/05/2026 21:03
BRIEF-Regeneron’S Ebola Antibody Recommended By World Health Organization For Investigational Use In Response To Current Bundibugyo Ebolavirus Outbreak May 28 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON’S EBOLA ANTIBODY RECOMMENDED BY WORLD HEALTH ORGANIZATION FOR INVESTIGATIONAL USE IN RESPONSE TO CURRENT BUNDIBUGYO EBOLAVIRUS OUTBREAK
REGENERON PHARMACEUTICALS INC: MAFTIVIMAB HAS BEEN RECOMMENDED TO BE STUDIED AS A MONOTHERAPY IN CURRENT OUTBREAK
REGENERON PHARMACEUTICALS - PREPARING MAFTIVIMAB SUPPLY FOR CLINICAL TRIALS; INMAZEB AVAILABLE IN DRC
REGENERON PHARMACEUTICALS INC: MAFTIVIMAB SHOWN BROAD ACTIVITY IN VITRO AGAINST MULTIPLE EBOLA SPECIES, INCLUDING BUNDIBUGYO
REGENERON PHARMACEUTICALS INC - SUPPLY OF INMAZEB IS ALREADY ON GROUND IN DRC
Source text: ID:nGNX463hDw
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)